DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK® (technetium Tc99m tilmanocept) injection from Norgine B.V. (“Norgine”).… Read More..

PRINCETON, N.J., May 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of immunogenicity studies for RiVax® (heat stable ricin toxin vaccine) identifying… Read More..

Noreen R. Henig, MD appointed as Chief Medical Officer Additional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020 IND submission for KZR-261, a first-in-class protein secretion inhibitor, is on track for Q1 2021 Cash, cash equivalents and marketable… Read More..